A61P 11 - Drugs for disorders of the respiratory system

Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2002
11/12/2002	US6479670 Selective retinoid acid receptor agonists
11/12/2002	US6479666 Phenyl-keto-imidazolidine thioamide derivatives
11/12/2002	US6479663 Intermediates useful for the preparation of antihistaminic piperidine derivatives
11/12/2002	US6479554 Immunotherapeutic agents
11/12/2002	US6479544 Therapeutic combinations of fatty acids
11/12/2002	US6479527 Bicyclic pyrrole derivatives as MCP-1 inhibitors
11/12/2002	US6479519 Inhibitors of cell adhesion; treatment of asthma or inflammatory bowel disease
11/12/2002	US6479518 Zwitterionic tachykinin receptor antagonists
11/12/2002	US6479507 Modulation of these inflammatory cytokines is considered one of the most effective strategies to block chronic inflammation and have positive therapeutic outcomes
11/12/2002	US6479505 6-arylphenanthridines with PDE-IV inhibiting activity
11/12/2002	US6479494 Arylalkanoyl pyridazines
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479483 3,4,6-substituted pyridine derivatives useful for treating depression and pain, resulting from inflammatory conditions, such as migraine, rheumatoid arthritis, asthma and inflamatory bowel disease; nk1 receptor antagonist
11/12/2002	US6479477 Substituted porphyrins
11/12/2002	US6479283 Stimulation, culture and preservation of pancreatic cells
11/12/2002	US6479035 Pharmaceutical formulation of fluticasone propionate
11/12/2002	CA2088289C Pharmaceutically active composition extracted from tanacetum parthenium, process for its extraction, and pharmaceutical composition containing same
11/09/2002	CA2385412A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088349A1 Method of examining allergic disease using cathepsin-c alternative splicing form as indication
11/07/2002	WO2002088317A2 Fusion molecules and methods for treatment of immune diseases
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088167A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088138A1 Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
11/07/2002	WO2002088123A1 Chemical compounds
11/07/2002	WO2002088121A1 Pyrazolo[1,5-a]pyridines and medicines containing the same
11/07/2002	WO2002088111A1 Novel benzylpiperidine compound
11/07/2002	WO2002088107A1 Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002088094A1 2-iminoimidazole derivatives (1)
11/07/2002	WO2002088092A1 2-iminoimidazole derivative (2)
11/07/2002	WO2002088084A1 Heterocyclic compound derivatives and medicines
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088078A2 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES
11/07/2002	WO2002087605A2 Modified fvii in treatment of ards
11/07/2002	WO2002087596A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087559A1 Potassium channel opener
11/07/2002	WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	WO2002087511A2 Modulators of elastase inhibitor secretion
11/07/2002	WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	WO2002087424A2 Treatment and diagnosis of macrophage mediated disease
11/07/2002	WO2002066026A3 Tramadol-based medicament
11/07/2002	WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002	WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002	WO2002028897A3 Human g-protein coupled receptor and uses thereof
11/07/2002	WO2002028424A3 Kyberdrug as autovaccines with immune-regulating effects
11/07/2002	WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002	US20020165402 Quarternary ammonium compounds
11/07/2002	US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165374 Secreted protein HFEAF41
11/07/2002	US20020165273 Carbamate compounds for use in preventing or treating neurodegenerative disorders
11/07/2002	US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002	US20020165239 Conjugates of sodium channel blockers and methods of using the same
11/07/2002	US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002	US20020165234 Selective B3 adrenergic agonists
11/07/2002	US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002	US20020165211 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002	US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002	US20020165119 Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
11/07/2002	US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002	US20020164704 Novel human monocyte chemotactic proprotein
11/07/2002	US20020164697 Nucleotide sequences coding polypeptides for use in treatment of autoimmune disease
11/07/2002	US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002	US20020164600 PD-L2 molecules: novel PD-1 ligands and uses therefor
11/07/2002	US20020164377 Mixture of retinoic acid and paclitaxel; polymeric carrier
11/07/2002	US20020164355 Test to detect antibodies; calibration
11/07/2002	US20020164352 Dietetics; anticholesterol agents; antidiabetic agents
11/07/2002	US20020164331 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
11/07/2002	US20020164326 Genetic engineering; administering immunoglobulins
11/07/2002	US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446079A1 Modulators of elastase inhibitor secretion
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002	CA2445811A1 Modified fvii in treatment of ards
11/07/2002	CA2445702A1 Control of compactability through crystallization
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445348A1 Novel benzylpiperidine compound
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2445330A1 Potassium channel opener
11/07/2002	CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002	CA2444911A1 Fusion molecules and methods for treatment of immune diseases
11/07/2002	CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient

1 ... 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 ... 878